Concepedia

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

Veronika K. Jaeger, Hal M. Hoffman, Tom van der Poll, Hugh H. Tilson, Julia Seibert, Antonio Speziale, G. Junge, Kristina Franke, Eleni Vritzali, Philip N. Hawkins,

Lara D. Veeken · 2017 · 56 citations · 10 references

DOIFull text

Open access

Abstract

Pneumococcal vaccines, unlike other vaccines, frequently trigger severe local and systemic inflammation in CAPS patients. Clinicians must balance potential benefits of pneumococcal immunization against safety concerns. The 13-valent pneumococcal conjugate vaccine might be favourable over the polysaccharide vaccine in CAPS patients.

References

10

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

Stephanie C. Eisenbarth, Oscar R. Colegio, William O’Connor et al. · Nature · 2008 · 1.5K citations · Full text

, , +9

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

J. Pekka Nuorti, Cynthia G. Whitney · MMWR Morbidity and Mortality Weekly Report · 2010 · 373 citations

, , +8

Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4

Edel A. McNeela, Áine Burke, Daniel R. Neill et al. · PLoS Pathogens · 2010 · 351 citations · Full text

, , +23

The NLRP3 Inflammasome Is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia

Martin Witzenrath, Florence Pache, D. Lorenz et al. · The Journal of Immunology · 2011 · 248 citations · Full text

, , +20

Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus

Ori Elkayam, Daphna Paran, Dan Caspi et al. · Clinical Infectious Diseases · 2002 · 185 citations · Full text